Literature DB >> 11342457

Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation.

M S Boosalis1, R Bandyopadhyay, E H Bresnick, B S Pace, K Van DeMark, B Zhang, D V Faller, S P Perrine.   

Abstract

Current chemotherapeutic and butyrate therapeutics that induce fetal hemoglobin expression generally also suppress erythropoiesis, limiting the production of cells containing fetal hemoglobin (F cells). Recently, selected short-chain fatty acid derivatives (SCFADs) were identified that induce endogenous gamma-globin expression in K562 cells and human burst-forming units-erythroid and that increase proliferation of human erythroid progenitors and a multilineage interleukin-3-dependent hematopoietic cell line. In this report, gamma-globin inducibility by these SCFADs was further demonstrated in mice transgenic for the locus control region and the entire beta-globin gene locus in a yeast artificial chromosome and in 2 globin promoter-reporter assays. Conditioned media experiments strongly suggest that their proliferative activity is a direct effect of the test compounds. Investigation of potential mechanisms of action of these SCFADs demonstrates that these compounds induce prolonged expression of the growth-promoting genes c-myb and c-myc. Both butyrate and specific growth-stimulatory SCFADs induced prolonged signal transducer and activator of transcription (STAT)-5 phosphorylation and activation, and c-cis expression, persisting for more than 120 minutes, whereas with IL-3 alone phosphorylation disappeared within minutes. In contrast to butyrate treatment, the growth-stimulating SCFADs did not result in bulk histone H4 hyperacetylation or induction of p21(Waf/Cip), which mediates the suppression of cellular growth by butyrate. These findings suggest that the absence of bulk histone hyperacetylation and p21 induction, but prolonged induction of cis, myb, myc, and STAT-5 activation, contribute to the cellular proliferation induced by selected SCFADs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342457      PMCID: PMC4263369          DOI: 10.1182/blood.v97.10.3259

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  83 in total

1.  Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin.

Authors:  E Skarpidi; G Vassilopoulos; Q Li; G Stamatoyannopoulos
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

2.  The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase.

Authors:  L Cuisset; L Tichonicky; P Jaffray; M Delpech
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

3.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

Authors:  C Van Lint; S Emiliani; E Verdin
Journal:  Gene Expr       Date:  1996

Review 4.  STATs: signal transducers and activators of transcription.

Authors:  J N Ihle
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

Review 5.  Multiple functions of dynamic histone acetylation.

Authors:  J R Davie; M J Hendzel
Journal:  J Cell Biochem       Date:  1994-05       Impact factor: 4.429

6.  Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells.

Authors:  Y Zimra; L Wasserman; L Maron; M Shaklai; A Nudelman; A Rephaeli
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

7.  Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.

Authors:  E Fibach; P Prasanna; G P Rodgers; D Samid
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

8.  Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy.

Authors:  T Ikuta; Y W Kan; P S Swerdlow; D V Faller; S P Perrine
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

9.  Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31.

Authors:  R H Charollais; C Buquet; J Mester
Journal:  J Cell Physiol       Date:  1990-10       Impact factor: 6.384

10.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation.

Authors:  J E Damen; H Wakao; A Miyajima; J Krosl; R K Humphries; R L Cutler; G Krystal
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  29 in total

1.  Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells.

Authors:  Shalini A Muralidhar; Valya Ramakrishnan; Inderdeep S Kalra; Wei Li; Betty S Pace
Journal:  J Biol Chem       Date:  2010-11-13       Impact factor: 5.157

Review 2.  Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease.

Authors:  Betty S Pace; Li Liu; Biaoru Li; Levi H Makala
Journal:  Exp Biol Med (Maywood)       Date:  2015-08

3.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

4.  Regulation of γ-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway.

Authors:  Valya Ramakrishnan; Betty S Pace
Journal:  Blood Cells Mol Dis       Date:  2011-04-15       Impact factor: 3.039

5.  Fetal globin induction--can it cure beta thalassemia?

Authors:  Susan P Perrine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

6.  An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo.

Authors:  Douglas V Faller; Serguei A Castaneda; Daohong Zhou; Merriline Vedamony; Peter E Newburger; Gary L White; Stanley Kosanke; P Artur Plett; Christie M Orschell; Michael S Boosalis; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2016-10-31       Impact factor: 3.039

7.  Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2.

Authors:  Jose Sangerman; Moo Seung Lee; Xiao Yao; Eugene Oteng; Cheng-Hui Hsiao; Wei Li; Sima Zein; Solomon F Ofori-Acquah; Betty S Pace
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

8.  Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.

Authors:  Soo-Hee Park; Christopher A Wiwi; David J Waxman
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

9.  Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Authors:  Robert A Parise; Jan H Beumer; Cyrous O Kangani; Julianne L Holleran; Julie L Eiseman; Nicola F Smith; Joseph M Covey; Susan P Perrine; Merrill J Egorin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-08       Impact factor: 3.205

10.  A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth Ataga; Marvin Reid; Elliott P Vichinsky; Lynne Neumayr; Loray Blair-Britt; Richard Labotka; Jonathan Glass; Jeffrey R Keefer; William A Wargin; Ronald Berenson; Susan P Perrine
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.